Search / 216192 results found

from
to
  • Updated

LOS ANGELES, Dec. 3, 2021 /PRNewswire/ -- Fiji Airways welcomed fully vaccinated tourists onboard for the first time in 20 months, with the first American tourists from Los Angles waking up in Fijian Paradise at around 5.45am on 2nd December (Fiji time), to a big bula welcome and celebration from the local community.

  • Updated

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tenet Fintech Group Inc. (f/k/a Peak Fintech Group Inc. ("Tenet"or the "Company") (OTCMKT: PKKFF) (NASDAQ: TNT).  Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

  • Updated

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eargo, Inc. ("Eargo" or the "Company") (NASDAQ: EAR) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08597, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Eargo securities between February 25, 2021 and September 22, 2021, inclusive (the "Class Period").  Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").

  • Updated

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) and certain of its officers.  The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 21-cv-02910, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Novavax securities between March 2, 2021 and October 19, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • Updated

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • Updated

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly") (NYSE: LLY), announce that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List ("NRDL") for all approved indications, according to the latest announcement from the China National Healthcare Security Administration ("NHSA"). The updated NRDL will officially take effect on January 1, 2022.